論文

Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A).

Kashiwada T, Shinozaki K, Ueno S, Kawanaka H, Uno F, Okita Y, Fukahori M, Matsushita H, Emi Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Maehara Y, Mori M, Baba E; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2021 Feb;26(2):345-354. doi: 10.1007/s10147-020-01803-w. Epub 2020 Oct 21.　PMID: 33085058